Stock Events

Stock Events

Immuneering 

$4.64
62
-$0.14-2.93% Friday 19:59
+$0.11+2.37%Friday 23:32After hours

Statistics

Day High
4.69
Day Low
4.62
52W High
10.08
52W Low
2.9
Volume
114,250
Avg. Volume
-
Mkt Cap
300.2M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.58
-0.46
-0.33
-0.21
Expected EPS
-0.268786
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-56.03MNet Income

Analyst Ratings

15.50Average Price Target
The highest estimate is 20.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMRX. It's not an investment recommendation.
NVIDIA
12
NVDA
Tesla
10
TSLA
AMD
10
AMD
Microsoft
9
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious genetic diseases, similar to Immuneering's focus on leveraging bioinformatics for drug development.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals competes in the biotech space with a strong emphasis on genetic and genomic analysis to develop drugs, aligning with Immuneering's approach to disease understanding.
AMGEN
AMGN
Mkt Cap196.12B
Amgen is a biotechnology pioneer that competes with Immuneering in the development of novel therapeutics, particularly in the oncology and inflammation sectors.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas overlapping with Immuneering's interests, including cancer and inflammatory diseases.
Biogen
BIIB
Mkt Cap29.4B
Biogen competes with Immuneering by focusing on the development of therapies for neurological and neurodegenerative diseases, a potential area of interest for Immuneering's bioinformatics-driven drug discovery.
Novartis
NVS
Mkt Cap293.94B
Novartis is a global healthcare company that competes across a broad range of therapeutic areas, including those targeted by Immuneering's drug development efforts.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is a global pharmaceutical company with a wide range of products that compete with Immuneering's efforts in drug discovery and development, especially in the oncology space.
Merck
MRK
Mkt Cap305.12B
Merck & Co. is known for its innovative medicines and vaccines, including cancer treatments that compete with Immuneering's focus on developing novel therapeutics using computational biology.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb is a competitor due to its extensive portfolio in oncology, immunology, and cardiovascular diseases, areas that Immuneering may target through its computational drug discovery platform.
Lilly(Eli) &
LLY
Mkt Cap1.06T
Eli Lilly and Company competes with Immuneering by investing heavily in bioinformatics and computational biology to accelerate drug discovery and development in areas like oncology and diabetes.

About

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Show more...
CEO
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Employees
37
Country
United States
ISIN
US45254E1073

Listings

BOATS
BOATS
IMRX.BOATS
XNAS
US
IMRX

0 Comments

Share your thoughts

FAQ

What is Immuneering stock price today?▼
The current price of IMRX is $4.64 USD — it has decreased by -2.93% in the past 24 hours. Watch Immuneering stock price performance more closely on the chart.
What is Immuneering stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Immuneering stocks are traded under the ticker IMRX.
Is Immuneering stock price growing?▼
IMRX stock has fallen by -9.2% compared to the previous week, the month change is a +5.22% rise, over the last year Immuneering has showed a +12.35% increase.
What is Immuneering market cap?▼
Today Immuneering has the market capitalization of 300.2M
When is the next Immuneering earnings date?▼
Immuneering is going to release the next earnings report on August 12, 2026.
What were Immuneering earnings last quarter?▼
IMRX earnings for the last quarter are -0.21 USD per share, whereas the estimation was -0.25 USD resulting in a +16.67% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immuneering revenue for the last year?▼
Immuneering revenue for the last year amounts to 0 USD.
What is Immuneering net income for the last year?▼
IMRX net income for the last year is -56.03M USD.
How many employees does Immuneering have?▼
As of July 19, 2026, the company has 37 employees.
In which sector is Immuneering located?▼
Immuneering operates in the Health & Wellness sector.
When did Immuneering complete a stock split?▼
Immuneering has not had any recent stock splits.
Where is Immuneering headquartered?▼
Immuneering is headquartered in Cambridge, United States.